Results 11 to 20 of about 983,540 (218)

mRNA-1273 is placenta-permeable and immunogenic in the fetus [PDF]

Molecular Therapy: Nucleic Acids
COVID-19 mRNA vaccines are generally recognized as safe for gestational administration. However, their transplacental pharmacokinetics remain obscure. In this study, mRNA-1273 intramuscularly given to pregnant mice rapidly circulated in maternal blood ...
Jeng-Chang Chen, Mei-Hua Hsu, Rei-Lin Kuo, Li-Ting Wang, Ming-Ling Kuo, Li-Yun Tseng, Hsueh-Ling Chang, Cheng-Hsun Chiu   +7 more
doaj   +3 more sources

Clinical Course, Outcomes, and Risk Factors of Myocarditis and Pericarditis Following Administration of mRNA-1273 Vaccination: A Protocol for a Federated Real-World Evidence Vaccine Safety Study Using Data from Five European Data Sources [PDF]

Vaccines
Background: Myocarditis and pericarditis are recognised risks following COVID-19 vaccination, including the mRNA-1273 vaccine. Most cases occur shortly following the second dose of this vaccine, and incidence is highest among young males. However, little
Laura C. Zwiers, Diederick E. Grobbee, Rob Schneijdenberg, Corine Baljé, Samantha St. Laurent, Daina B. Esposito, Lei Zhu, Veronica V. Urdaneta, Magalie Emilebacker, Daniel Weibel, Felipe Villalobos, Carlo Alberto Bissacco, Arantxa Urchueguía Fornes, Juan José Carreras-Martínez, Anteneh A. Desalegn, Angela Lupattelli, Lei Wang, Jannik Wheler, Vera Ehrenstein, Denise Morris, Catherine Fry, Marjolein Jansen, Brianna M. Goodale, David S. Y. Ong   +23 more
doaj   +5 more sources

Profiling antibody epitopes induced by mRNA-1273 vaccination and boosters [PDF]

Frontiers in Immunology
BackgroundCharacterizing the antibody epitope profiles of messenger RNA (mRNA)-based vaccines against SARS-CoV-2 can aid in elucidating the mechanisms underlying the antibody-mediated immune responses elicited by these vaccines.MethodsThis study ...
Bethany Girard, Elisabeth Baum-Jones, Rebecca L. Best, Thomas W. Campbell, Jack Coupart, Kyla Dangerfield, Abhilash Dhal, Michael Jhatro, Brian Martinez, Jack Reifert, John Shon, Minlu Zhang, Rebecca Waitz, Spyros Chalkias, Darin K. Edwards, Maha Maglinao, Robert Paris, Rolando Pajon   +17 more
doaj   +5 more sources

Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers [PDF]

International Journal of Infectious Diseases, 2022
Objectives: There are limited comparative immunologic durability data post COVID-19 vaccinations. Methods: Approximately 8.4 months after primary COVID-19 vaccination, 647 healthcare workers completed surveys about COVID-19 vaccinations/infections and ...
Wendy M. Brunner, Daniel Freilich, Jennifer Victory, Nicole Krupa, Melissa B. Scribani, Paul Jenkins, Emily G. Lasher, Amanda Fink, Anshini Shah, Peggy Cross, Valerie Bush, Laura J. Peek, Gary A. Pestano, Anne M. Gadomski   +13 more
doaj   +2 more sources

Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study. [PDF]

PLoS Medicine, 2022
BackgroundMyocarditis and pericarditis following the Coronavirus Disease 2019 (COVID-19) mRNA vaccines administration have been reported, but their frequency is still uncertain in the younger population.
Marco Massari, Stefania Spila Alegiani, Cristina Morciano, Matteo Spuri, Pasquale Marchione, Patrizia Felicetti, Valeria Belleudi, Francesca Romana Poggi, Marco Lazzeretti, Michele Ercolanoni, Elena Clagnan, Emanuela Bovo, Gianluca Trifirò, Ugo Moretti, Giuseppe Monaco, Olivia Leoni, Roberto Da Cas, Fiorella Petronzelli, Loriana Tartaglia, Nadia Mores, Giovanna Zanoni, Paola Rossi, Sarah Samez, Cristina Zappetti, Anna Rosa Marra, Francesca Menniti Ippolito, TheShinISS-Vax|COVID Surveillance Group   +26 more
doaj   +3 more sources

Breakhthrough Infection Pasca Pemberian Booster mRNA Heterolog pada Tenaga Kesehatan di RSUD Arifin Achmad [PDF]

Majalah Kedokteran Andalas, 2023
Tujuan: Mengetahui prevalensi dan karakteristik responden breakthrough infection pada tenaga kesehatan di RSUD Arifin Achmad Provinsi Riau dalam 14 hari – 6 bulan pasca vaksinasi booster mRNA-1273. Metode: Metode penelitian cross sectional yang dilakukan
Dina Br Nababan, Eka Bebasari, Ligat Pribadi Sembiring, Dani Rosdiana, Rahmat Azhari Kemal   +4 more
doaj   +3 more sources

Myocarditis and pericarditis in individuals exposed to the Ad26.COV2.S, BNT162b2 mRNA, or mRNA-1273 SARS-CoV-2 vaccines [PDF]

Frontiers in Cardiovascular Medicine, 2023
ImportanceThere is a high level of public and professional interest related to potential safety issues of the COVID-19 vaccines; however, no serious adverse cardiovascular events were reported in phase 3 randomized controlled trials of their safety and ...
Manan Pareek, Manan Pareek, Pasquale Sessa, Paolo Polverino, Francesco Sessa, Kristian Hay Kragholm, Maurizio Sessa   +6 more
doaj   +4 more sources

Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results [PDF]

Frontiers in Immunology, 2021
Background: BNT162b2 and mRNA-1273 are the two recently approved mRNA-based vaccines against COVID-19 which has shown excellent safety and efficacy. Preliminary data about specific and neutralizing antibodies is available covering the first 100 days ...
Andrea Lombardi, Andrea Lombardi, Giorgio Bozzi, Riccardo Ungaro, Simone Villa, Valeria Castelli, Davide Mangioni, Antonio Muscatello, Andrea Gori, Andrea Gori, Andrea Gori, Alessandra Bandera, Alessandra Bandera, Alessandra Bandera   +13 more
doaj   +3 more sources

Reactogenicity to the mRNA-1273 Booster According to Previous mRNA COVID-19 Vaccination [PDF]

Vaccines, 2022
The objective of this study was to assess the local and systemic adverse reactions after the administration of a COVID-19 mRNA-1273 booster between December 2021 and February 2022 by comparing the type of mRNA vaccine used as primary series (mRNA-1273 or
Oleguer Parés-Badell, Ricardo Zules-Oña, Lluís Armadans, Laia Pinós, Blanca Borrás-Bermejo, Susana Otero, José Ángel Rodrigo-Pendás, Martí Vivet-Escalé, Yolima Cossio-Gil, Antònia Agustí, Cristina Aguilera, Magda Campins, Xavier Martínez-Gómez   +12 more
doaj   +5 more sources

Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase [PDF]

New England Journal of Medicine, 2021
BACKGROUND At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease 2019 (Covid-19).
Anderson, EJ, August, A, Babiker, A, Baden, LR, Bruno, R, Campbell, TB, Clark, J, Clouting, H, Cooper, LA, Corey, L, Deng, W, Doblecki-Lewis, S, Eder, F, El Sahly, HM, Ellenberg, SS, Essink, B, Faugno, A, Feldman, G, Fichtenbaum, CJ, Fix, A, Follmann, D, Gilbert, P, Gorman, R, Graham, BS, Griffin, M, Hamill, RJ, Hamilton, H, Han, S, Han-Conrad, L, Horwith, G, Huynh, C, Jackson, LA, Janes, H, Joffe, S, Kalil, J, Kennelly, C, Leav, B, Ledgerwood, JE, Levin, M, Levine, MM, Lipsitz, L, Makgoba, MW, Manzo, D, Marovich, M, Martin, JM, Mascola, JR, Miller, J, Moore, RH, Mytle, N, Neuzil, KM, Pajon, R, Pavetto, C, Polakowski, L, Rankin, B, Rosenberg, ES, Schödel, F, Tomassini, JE, Tong, X, Treanor, J, Tsiatis, AA, Whitley, RJ, Zervos, M, Zhou, H   +62 more
core   +2 more sources